港股異動 | 中國建築國際續升超4% 5日連漲近20% 港澳建築市場龍頭地位穩固
格隆匯8月22日丨中國建築國際(3311.HK)延續漲勢,續升超4%,5日連漲近20%。現報9.08港元創兩個半月新高價,總市值達457億港元。公司上週五午間公吿,上半年純利升20.4%至42.1億港元,派息24港仙。上半年,內地市場繼續推進轉型,特色總承包業務增長強勁,港澳建築市場龍頭地位穩固,幕牆業務保持技術領先和高速增長。與此同時,集團保持了穩健的財務狀況,抗風險能力持續加強。於2022年6月30日,集團在手總合約額約為4999.4億港元,其中未完合約額約為2851億港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.